MiMedx to Present at the 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

MARIETTA, Ga., Dec. 07, 2020 - MiMedx Group, Inc. (Nasdaq: MDXG) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 4:30 PM EST. The company, known for its advanced wound care solutions, invites institutional investors to connect with management through J.P. Morgan representatives. A live webcast can be accessed on the company's website, with a replay available post-presentation. MiMedx specializes in human placental tissue allografts and has supplied over two million allografts using its proprietary processes.

News Market Reaction – MDXG

-2.91%

-2.91% Session move

In the trading session that priced this news, MDXG declined 2.91%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MARIETTA, Ga., Dec. 07, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that management will present at the 39^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13^th at 4:30 PM EST. Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.

A webcast of the presentation will be available on the Events page of the Investors section of the Company’s website. A replay of the webcast will be available on the Company’s website at www.mimedx.com following the conclusion of the presentation.

About MiMedx
MiMedx^® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION^® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts:
Investors
Jack Howarth
404-360-5681

investorrelations@mimedx.com

FAQ

When is MiMedx's presentation at the J.P. Morgan Healthcare Conference?

MiMedx will present on January 13, 2021, at 4:30 PM EST.

How can I access the MiMedx conference presentation?

The presentation will be available via a live webcast on the Investors section of MiMedx's website.

What does MiMedx specialize in?

MiMedx specializes in advanced wound care and therapeutic biologics, focusing on human placental tissue allografts.

What is the stock symbol for MiMedx?

The stock symbol for MiMedx is MDXG.

How many allografts has MiMedx supplied?

MiMedx has supplied more than two million allografts.